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Abstract
Background: Breast cancer is a common malignancy, but metastases to the breast of extramammary malignancies
are very rare. Treatment and prognosis are different. The aim of the study is to report the incidence of lymphomas
and metastases to the breast of extramammary malignancies in our 30-year archive.
Methods: The pathology database of a single institute was reviewed for all breast neoplasms which were coded in
our system as a metastasis in the period 1985–2014. Metastatic tumors from primary breast carcinoma were
excluded.
Results: A total of 47 patients were included (7 men/40 women, mean age 63 years). The majority originated from
lymphoma (n = 18) and primary melanoma (n = 11). Other primary tumor sites included the ovary (n = 6), lung (n = 6),
colon (n = 3), kidney (n = 1), stomach (n = 1), and chorion (n = 1). In 24/47 patients (51 %), metastasis was the first sign
of the specific malignant disease. In seven patients (15 %) surgery was performed, the diagnosis of metastatic disease
was adjusted in four patients (9 %) postoperatively.
Conclusions: It is important to distinguish lymphomas and metastases to the breast from common primary breast
carcinoma for proper treatment and prognosis. Therefore, we emphasize the need for a histological or cytopathological
diagnosis before any treatment is commenced. The pathologist plays a key role in considering the diagnosis of metastasis
if the histological features are unusual for a primary breast carcinoma. The pathologist should therefore be properly
informed by the clinical physician although lymphomas and metastases to the breast are the first presentation of
malignant disease in half the cases.
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Background
Metastases from extramammary malignant neoplasms are
very rare, since they account for less than 2 % of all breast
malignancies [1]. In general, symptoms are similar in those
of primary mammary carcinoma, including palpable rela-
tively well-circumscribed and freely movable masses within
the breast, pain, tenderness, and inflammation. Non pri-
mary breast malignancies are generally well defined and
rounded, and calcification is unusual. On mammography,
these lesions can be mistaken for benign (fibroadenoma) as
well as primary breast malignancies [1, 2].
Metastasis from many extramammary neoplasms have
been described, such as lymphomas, malignant melanoma,
carcinomas of the lung, ovary, prostate, kidney, stomach,
small bowel, large bowel, thyroid, cervix, and soft tissues
[1, 3–8].
Distinction of metastases to the breast from extra-
mammary neoplasms from primary breast neoplasms is
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important for determining the best management. In pa-
tients with metastatic disease, a systemic and palliative
approach is usually more effective. Moreover, correct
diagnosis may prevent unnecessary surgery. The aim of
this study is to report the incidence of lymphomas and
metastases to the breast of extramammary malignancies
in our 30-year archive.
Methods
The pathology database of a single institute was used to
identify all breast neoplasms which were coded in our sys-
tem as a metastasis in the period of 30 years (1985–2014).
Each case was retrospectively reviewed by an experienced
pathologist in order to determine whether or not the malig-
nancy was rightly coded as non primary breast malignancy.
We also included secondary metastases from leukemia-
lymphomas to the breast. For all patients, histological re-
ports were reviewed to determine the primary site of the
tumor. We reviewed the first manifestation of the primary
tumor. Patients with metastatic tumors from primary
(contralateral) breast carcinoma were excluded. Additional
data were obtained from the hospital electronic record sys-
tem, retrospectively.
Results
In the study period, approximately 9000 breast cancers were
diagnosed in our laboratory. Fifty-nine of these patients with
breast neoplasms were coded as a metastasis. In total, 12
patients were excluded because of the following reasons: six
were coded incorrectly, they were diagnosed with primary
breast cancer, three were excluded because of incomplete
information, one was diagnosed with a metastatic tumor
from primary breast carcinoma, and two were skin tumors
involving the breast, respectively, one squamous cell carcin-
oma and one primary T cell lymphoma. The final study
group comprised 47 patients (Table 1). Females were more
frequently affected (7 men, 40 women). The mean age was
63 years (range 32–87). The metastases appeared on average
after 39 months (range 1–273) after diagnosis of primary
extramammary malignancy. In 24 of the 44 patients (51 %),
the metastasis was the first sign of the specific malignant
disease.
The histology of extramammary breast neoplasms is
shown in Table 2. The most common primary neoplasm
was lymphoma, followed by melanoma. Other primary
tumor sites included the ovary, lung, colon, kidney, stom-
ach, and the chorion. In three patients with melanoma
(27 % [3/11]), no primary site was found, most probably
due to complete regression of a skin melanoma. All 18
mammary lymphomas were B cell type lymphomas (13
primary, 5 secondary).
The diagnosis in our group of 47 patients was obtained
by core biopsy or with fine-needle aspiration (Table 3). In
total, core biopsy was performed in 32 patients (68 %), 14
patients (30 %) had a fine-needle aspiration, and one patient
(2 %) was operated without preoperative diagnostics; in this
case, an intra-operative frozen section was performed.




Sex Number of patients (%)
Men 7 (15)
Women 40 (85)





Known malignant disease (incl. lymphomas) Number of patients (%)
No history of primary malignant disease 24 (51 %)
History of primary malignant disease 23 (49 %)
Table 2 Histology of breast metastases





Lymphoma 18 (38.3 %)
Primary 13
Secondary 5 5–64 (24)
Melanoma 11 (23.4 %)
No primary site 3
Primary side detected 8 4–273 (66)
Ovarian carcinoma 6 (12.8 %)
No history of ovarian carcinoma 1
History of ovarian carcinoma 5 1–43 (15)
Lung carcinoma 6 (12.8 %)
No history of lung carcinoma 4
History of lung carcinoma 2 10–28 (19)
Adenocarcinoma of the colon 3 (6.4 %)
No history of colon carcinoma 1
History of colon carcinoma 2 1–5 (3)
Renal cell carcinoma 1 (2.1 %)
No history of renal cell carcinoma 0
History of renal cell carcinoma 1 2 (−)
Adenocarcinoma of the stomach 1 (2.1 %)
No history of stomach carcinoma 1
History of stomach carcinoma 0 –
Choriocarcinoma 1 (2.1 %)
No history of choriocarcinoma 1
History of choriocarcinoma 0 –
Total 47 (100 %)
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Seven patients (15 %) had breast surgery. All underwent
modified radical mastectomy; the postoperative pathology
revealed three melanomas, two ovarian carcinomas, one
lymphoma, and one adenocarcinoma of the colon. In these
patients, the diagnosis was obtained by core biopsy in three;
in two of them, the preoperative diagnosis of primary breast
cancer was incorrect retrospectively (i.e., primary breast
carcinoma). The remaining patient had a correct preopera-
tive diagnosis, and the surgery was performed for palliation,
i.e., local control. Three patients had breast surgery after
diagnosis obtained by fine-needle aspiration; in one, there
was an incorrect preoperative diagnosis (i.e., primary breast
carcinoma), and two patients underwent palliative surgical
resection. One patient had no preoperative pathological
diagnosis; however, the intra-operative frozen section re-
vealed breast carcinoma, and after postoperative analyses,
this diagnosis was adjusted with ovarian carcinoma.
Discussion
Breast metastases of extramammary neoplasms are ex-
tremely rare. In our laboratory, we found a total of 47 pa-
tients with metastases to the breast from non mammary
primary in a 30-year period, representing an incidence of
approximately 0.5 %. In our study, lymphomas and melano-
mas were the most prevalent primary neoplasms (38 and
23 %, respectively), which is in accordance with previous
reported studies [1, 2, 4, 9]. Lee et al. reported gastric can-
cers to be the most common metastases to the breast.
However, gastric carcinoma is the most common form of
cancer in Korea and the incidence of melanoma is much
lower [10].
In our study, patients with breast metastases presented
with a mean of 39 months after diagnoses of primary
cancer. Patients with primary melanomas presented with
the largest time interval between primary presentation
and breast metastases with a mean of 66 months, prob-
ably reflecting the well-known natural history of melan-
oma with a subgroup showing late recurrence. Lee et al.
reported a mean time interval of 14 months, but this
difference in interval might be explained by the larger
amount of melanomas included in our study (23 vs
6 %) [10].
In this study, in four patients (9 %), the diagnosis had to
be corrected postoperatively. This percentage seems poor;
however, it should be considered that diagnosis of extra-
mammary metastasis to the breast is difficult not only
because clinical presentation may be similar to primary
breast malignancies but also because it may be the first
presentation of unknown metastatic disease. In addition,
the diagnosis is hard to make on cytology alone. Obviously,
proper clinical information may be helpful and should be
provided to the pathologist at all times.
Histological diagnosis is important to distinguish metas-
tases to the breast from common primary breast carcin-
oma for effective treatment and direct attention to the
extramammary primary, and in case of metastases to the
breast prevent unnecessary surgery. Lee et al. reviewed
histological and immunohistochemical features that are
useful in the diagnosis of metastases to the breast. They
discovered that about a third of the lesions do not show
specific histological features. Elastosis and carcinoma in
situ are common histological characteristics in primary
mammary cancers. Different types of carcinoma are sug-
gestive for specific origins, such as clear cell carcinoma for
renal origin, small cell carcinoma of pulmonary origin, and
papillary carcinoma of ovarian serous papillary carcinoma.
For malignant melanomas, the appearance of cytoplasmic
pigment, intranuclear inclusions, and spindle cells may be
useful clues [11].
Immunohistochemical panels can be of great value when
trying to distinguish mammary carcinoma from common
metastases to the breast. A mammary origin can be
supported by the expression of estrogen receptor, proges-
terone receptor, her2neu, and GCDFP-15. Recently, GATA-
3 has been shown to be a sensitive marker for breast cancer
[12, 13]. However, these markers are not entirely specific,
e.g., estrogen receptor can be expressed in ovarian cancer
and GATA-3 is also a sensitive marker for urothelial cancer.
Sensitive markers for the metastases that we found in our
series are summarized in Table 4 [14, 15]. These markers
should always be used in a panel of antibodies since no
single marker is completely sensitive or specific. These
markers are readily available on core biopsies but can also
be applied to cytological specimens.
Several authors emphasized the usages of fine-needle
cytology [16–19]. Fulciniti et al. emphasized the usage of
cytopathological criteria in combination with immuno-
cytochemistry when considering the diagnosis of metas-
tases to the breast [16]. As stated before, diagnosis of
metastases to the breast of non primary breast malig-
nancies should be performed by a combination of clin-
ical presentation and evaluation of the pathology and
specific antibodies.







Core biopsy 32 (68) 3 - Lymphoma (n = 1)
- Melanoma (n = 1)




14 (30) 3 - Melanoma (n = 2): palliative
resectiona
- Colon carcinoma (n = 1)
Frozen
section
1 (2) 1 - Ovarian carcinoma (n = 1)
Total (n) 47 (100) 7
aCorrect preoperative diagnosis
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Conclusions
It is concluded that although metastases to the breast
are rare, it should be considered in the differential diag-
nosis of breast cancer if the morphology is unusual for
primary breast malignancies and if there is a history of a
prior (treated) malignancy, in order to avoid unnecessary
surgery.
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